Dr. Reddy's Laboratories Limited (RDY)

IN — Healthcare Sector
Peers: PCRX  PAHC  COLL  SSIC  ANIP  ALKS  ITCI  EGRX  PBH  EVO  SUPN  DCPH 

Automate Your Wheel Strategy on RDY

With Tiblio's Option Bot, you can configure your own wheel strategy including RDY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RDY
  • Rev/Share 373.5748
  • Book/Share 385.8871
  • PB 3.5659
  • Debt/Equity 0.1608
  • CurrentRatio 1.9175
  • ROIC 0.1315

 

  • MktCap 1131261804147.7
  • FreeCF/Share 7.8206
  • PFCF 173.5863
  • PE 21.1075
  • Debt/Assets 0.1062
  • DivYield 0.0061
  • ROE 0.1792

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 2
  • DCF Score 4
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade RDY HSBC Securities Hold Buy -- $16.9 June 5, 2025
Downgrade RDY Nomura Buy Neutral -- -- Dec. 19, 2024

News

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
ALVO, RDY
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.

Read More
image for news RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
RDY
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)---- $RDY #Alvotech--Alvotech and Dr. Reddy's Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

Read More
image for news Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Dr. Reddy's Continues To Be A Good Buy At Current Valuation
RDY
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive

I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.

Read More
image for news Dr. Reddy's Continues To Be A Good Buy At Current Valuation
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
RDY
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive

Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Read More
image for news RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
Dr. Reddy's Q4 & Full Year FY25 Financial Results
RDY
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.

Read More
image for news Dr. Reddy's Q4 & Full Year FY25 Financial Results
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
RDY
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral

GUANGZHOU, China and HYDERABAD, India , March 27, 2025 /PRNewswire/ -- Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2506, a proposed Simponi® biosimilar.

Read More
image for news Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
ALVO, RDY
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive

Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.

Read More
image for news FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
RDY
Published: March 13, 2025 by: Business Wire
Sentiment: Neutral

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDYS--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.

Read More
image for news Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

About Dr. Reddy's Laboratories Limited (RDY)

  • IPO Date 2001-04-11
  • Website https://www.drreddys.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Erez Israeli M.B.A.
  • Employees 27048

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.